Related Experiment Video
Updated: May 17, 2026
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
High Eradication Rate of a Potassium-Competitive Acid Blocker-Based Minocycline, Furazolidone, and Bismuth Regimen
Ji-Yan Li1, Ying-Ying Han1, Dong-Yan Li2
1Division of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Background:
Management of refractory Helicobacter pylori (H. pylori) infection remains challenging due to increasing antibiotic resistance and limited effective rescue options. Minocycline and furazolidone retain low resistance rates, while potassium-competitive acid blockers (P-CABs) provide potent and sustained acid suppression. This study aimed to evaluate the efficacy and safety of a 14-day P-CAB-based regimen combining minocycline, furazolidone, and bismuth in patients with refractory H. pylori infection.
Methods:
From January 2023 to October 2025, clinical data were collected from patients with refractory H. pylori infection who received the above regimen at Tongji Hospital, Wuhan, China. Eradication was assessed by a urea breath test performed at least 4 weeks after treatment. Adverse events during treatment were recorded.
Results:
A total of 368 patients were included in modified intention-to-treat analysis. Of them, 183 (49.7%) had two previous eradication failures, 165 (44.8%) had three to four failures, and 20 (5.4%) had five or more failures. Among the 143 patients who underwent antibiotic resistance gene testing, the resistance rates to clarithromycin and quinolones were 96.5% and 79.7%, respectively. The H. pylori eradication rate was 92.7% (95% CI 89.5%-94.9%) in modified intention-to-treat analysis and 96.4% (95% CI 93.8%-97.9%) in per-protocol analysis. Adverse events occurred in 25.8% of patients and were predominantly mild to moderate, with dizziness (9.5%), nausea (5.2%), and abdominal distension (5.2%) most common. Poor compliance (OR = 18.14, 95% CI 6.39-51.51) and peptic ulcer (OR = 4.34, 95% CI 1.27-14.82) were independently associated with eradication failure.
Conclusions:
The 14-day regimen of P-CAB, minocycline, furazolidone, and bismuth is highly effective and well tolerated in patients with refractory H. pylori infection. This regimen represents a promising empirical rescue therapy, particularly in settings where antimicrobial susceptibility testing is unavailable.
More Related Videos
06:40Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance
Published on: July 28, 2023
04:56Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis
Published on: May 16, 2025
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:24Peptic Ulcer Disease II: Pathophysiology